The formulation of recombinant factor IX: stability, robustness, and convenience

Area of Science:

• Biochemistry
• Protein Formulation
• Pharmaceutical Sciences

Background:

• Recombinant factor IX (rFIX) is crucial for treating hemophilia B.
• Existing formulations may have stability limitations or require preservatives.
• Developing a stable, preservative-free rFIX formulation is essential for improved patient care.

Purpose of the Study:

• To develop and characterize a stable, lyophilized recombinant factor IX (rFIX) formulation.
• To evaluate the role of specific excipients in ensuring rFIX stability.
• To confirm the absence of blood or plasma products in the formulation and production.

Main Methods:

• Lyophilization of rFIX with histidine, glycine, sucrose, and polysorbate-80.
• Analytical characterization including clotting assays, SDS-PAGE, IEF, SEC, peptide mapping, oligosaccharide fingerprinting, and HPLC.
• Assessment of stability in both lyophilized and reconstituted states.

Main Results:

• The developed rFIX formulation is stable and contains no preservatives or blood products.
• Excipients (histidine, glycine, sucrose, polysorbate-80) were optimized for protein protection and cake morphology.
• Comprehensive analytical testing confirmed high long-term stability and excellent post-reconstitution stability.

Conclusions:

• An optimized, lyophilized rFIX formulation offers superior long-term stability and ease of use.
• The formulation's stability is attributed to the synergistic effects of its excipient combination.
• This preservative-free, non-blood-derived rFIX represents a significant advancement in hemophilia B treatment.